Ascend Wellness Q3 Revenue Grows 4.2% to $130M; Net Loss Widens to $28M
AAWH is trading near its 52-week low of $0.34 (3.2% above the low).
Summary
Ascend Wellness posted Q3 2026 revenue of $130.0 million, up 4.2% year-over-year, with Adjusted EBITDA of $31.1 million, but the net loss widened to $28.0 million as interest expense climbed to $22.0 million. The company ended the quarter with $63.6 million in cash against $260.4 million of net debt.
Key Events · Earnings and Guidance · AAWH
-
Q3 Revenue Returns to Growth
Net revenue was $130.0 million, up 3.1% sequentially from $126.1 million and 4.2% year-over-year from $124.7 million, driven by retail revenue of $97.8 million (up 5.5% sequentially).
-
Net Loss Widens to $28.0M
Net loss was $28.0 million versus $9.8 million in Q2 2026, which had included a one-time $14.8 million release from the reserve for uncertain tax positions. Interest expense rose to $22.0 million from $12.6 million a year earlier.
-
Cash Flow Positive After Interest Payment
Operating cash flow was $5.4 million even after the $19.1 million semi-annual interest payment, a $7.4 million improvement from Q3 2025; free cash flow was $2.7 million and capital expenditures were $4.8 million.
-
Balance Sheet Remains Levered
Cash and cash equivalents were $63.6 million at September 30, 2026, against net debt of $260.4 million and total stockholders' deficit of $112.4 million.
Analysis · AAWH · Life Sciences
Revenue returned to year-over-year growth and Adjusted EBITDA held at $31.1 million, but the bottom line deteriorated sharply: net loss widened to $28.0 million from $9.8 million in Q2, which had benefited from a one-time $14.8 million tax reserve release. Interest expense nearly doubled year-over-year to $22.0 million, and with $260.4 million of net debt against a $63.6 million cash balance, debt service is the dominant constraint on the equity. Even after a $19.1 million semi-annual interest payment, the company generated $5.4 million of operating cash flow, and it exceeded its 60-store target with 61 locations open. Q4 guidance calls for only 1-2% revenue growth with margins flat to Q3.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AAWH was trading at $0.35 on OTC in the Life Sciences sector, with a market capitalization of approximately $71.2M. The 52-week trading range was $0.34 to $1.20. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.